Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Southwest Pharmaceutical Wins Saridon Trademark Lawsuit

This article was originally published in PharmAsia News

Executive Summary

Southwest Pharmaceutical has received China's Supreme Court verdict, which affirmsthe State Administration for Industry and Commerce's judgment that the firm's Sanlietong trademark is valid. The Supreme Court believed that certain mistakes were committed during the fact-finding and legal application process, so the verdict in the first and second trials should be repealed. This ruling marks the end of a 10-year Saridon trademark lawsuit (PharmAsia News, June 16, 2008) and will have a positive impact for the company. In recent years, pharmaceutical MNCs have been filing suits against Sanlietong, interfering with the company's marketing activities. Even so, the product's revenue for 2008 grew 30 percent to RMB 48 million, reflecting the drug's popularity and potential. (Click here for more - Chinese Language)

Table

View full table

Tags:
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC071911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By